Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Identifieur interne : 003A13 ( Main/Exploration ); précédent : 003A12; suivant : 003A14Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Auteurs : Robert J. Motzer [États-Unis] ; Camillo Porta [Italie] ; Nicholas J. Vogelzang [États-Unis] ; Cora N. Sternberg [Italie] ; Cezary Szczylik [Pologne] ; Jakub Zolnierek [Pologne] ; Christian Kollmannsberger [Canada] ; Sun Young Rha [Corée du Sud] ; Georg A. Bjarnason [Canada] ; Bohuslav Melichar [République tchèque] ; Ugo De Giorgi [Italie] ; Viktor Grünwald [Allemagne] ; Ian D. Davis [Australie] ; Jae-Lyun Lee [Corée du Sud] ; Emilio Esteban [Espagne] ; Gladys Urbanowitz [États-Unis] ; Can Cai [États-Unis] ; Matthew Squires [Suisse] ; Mahtab Marker [États-Unis] ; Michael M. Shi [États-Unis] ; Bernard Escudier [France]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Benzimidazoles (effets indésirables), Benzimidazoles (usage thérapeutique), Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs), Femelle, Humains, Inhibiteurs de protéines kinases (usage thérapeutique), Mâle, Métastase tumorale, Nicotinamide (analogues et dérivés), Nicotinamide (effets indésirables), Nicotinamide (usage thérapeutique), Néphrocarcinome (mortalité), Néphrocarcinome (secondaire), Néphrocarcinome (traitement médicamenteux), Phénylurées (effets indésirables), Phénylurées (usage thérapeutique), Quinolinone (effets indésirables), Quinolinone (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du rein (mortalité), Tumeurs du rein (traitement médicamenteux).
- MESH :
- analogues et dérivés : Nicotinamide.
- antagonistes et inhibiteurs : Facteur de croissance endothéliale vasculaire de type A.
- effets indésirables : Benzimidazoles, Nicotinamide, Phénylurées, Quinolinone.
- mortalité : Néphrocarcinome, Tumeurs du rein.
- secondaire : Néphrocarcinome.
- traitement médicamenteux : Néphrocarcinome, Tumeurs du rein.
- usage thérapeutique : Antinéoplasiques, Benzimidazoles, Inhibiteurs de protéines kinases, Nicotinamide, Phénylurées, Quinolinone.
- Adolescent, Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Métastase tumorale, Sujet âgé, Sujet âgé de 80 ans ou plus.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents (therapeutic use), Benzimidazoles (adverse effects), Benzimidazoles (therapeutic use), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (mortality), Carcinoma, Renal Cell (secondary), Female, Humans, Kidney Neoplasms (drug therapy), Kidney Neoplasms (mortality), Male, Middle Aged, Neoplasm Metastasis, Niacinamide (adverse effects), Niacinamide (analogs & derivatives), Niacinamide (therapeutic use), Phenylurea Compounds (adverse effects), Phenylurea Compounds (therapeutic use), Protein Kinase Inhibitors (therapeutic use), Quinolones (adverse effects), Quinolones (therapeutic use), Vascular Endothelial Growth Factor A (antagonists & inhibitors).
- MESH :
- chemical , adverse effects : Benzimidazoles, Niacinamide, Phenylurea Compounds, Quinolones.
- chemical , analogs & derivatives : Niacinamide.
- chemical , antagonists & inhibitors : Vascular Endothelial Growth Factor A.
- chemical , therapeutic use : Antineoplastic Agents, Benzimidazoles, Niacinamide, Phenylurea Compounds, Protein Kinase Inhibitors, Quinolones.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- mortality : Carcinoma, Renal Cell, Kidney Neoplasms.
- secondary : Carcinoma, Renal Cell.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Metastasis.
Abstract
An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma.
DOI: 10.1016/S1470-2045(14)70030-0
PubMed: 24556040
Affiliations:
- Allemagne, Australie, Canada, Corée du Sud, Espagne, France, Italie, Pologne, République tchèque, Suisse, États-Unis
- Latium, Nevada, New Jersey, Région capitale de Séoul, État de New York
- Rome, Séoul
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003913
- to stream PubMed, to step Curation: 003798
- to stream PubMed, to step Checkpoint: 003798
- to stream Ncbi, to step Merge: 001801
- to stream Ncbi, to step Curation: 001801
- to stream Ncbi, to step Checkpoint: 001801
- to stream Main, to step Merge: 003A56
- to stream Main, to step Curation: 003A13
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.</title><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan-Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Porta, Camillo" sort="Porta, Camillo" uniqKey="Porta C" first="Camillo" last="Porta">Camillo Porta</name><affiliation wicri:level="1"><nlm:affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name><affiliation wicri:level="2"><nlm:affiliation>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Comprehensive Cancer Centers of Nevada, Las Vegas, NV</wicri:regionArea><placeName><region type="state">Nevada</region></placeName></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation wicri:level="3"><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Camillo and Forlanini Hospitals, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Szczylik, Cezary" sort="Szczylik, Cezary" uniqKey="Szczylik C" first="Cezary" last="Szczylik">Cezary Szczylik</name><affiliation wicri:level="1"><nlm:affiliation>Military Institute of Health Services in Warsaw, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Military Institute of Health Services in Warsaw, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Zolnierek, Jakub" sort="Zolnierek, Jakub" uniqKey="Zolnierek J" first="Jakub" last="Zolnierek">Jakub Zolnierek</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Institute, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Institute, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Kollmannsberger, Christian" sort="Kollmannsberger, Christian" uniqKey="Kollmannsberger C" first="Christian" last="Kollmannsberger">Christian Kollmannsberger</name><affiliation wicri:level="1"><nlm:affiliation>BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name><affiliation wicri:level="3"><nlm:affiliation>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name><affiliation wicri:level="1"><nlm:affiliation>Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sunnybrook Odette Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Melichar, Bohuslav" sort="Melichar, Bohuslav" uniqKey="Melichar B" first="Bohuslav" last="Melichar">Bohuslav Melichar</name><affiliation wicri:level="1"><nlm:affiliation>Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Palacký University Medical School and Teaching Hospital, Olomouc</wicri:regionArea><wicri:noRegion>Olomouc</wicri:noRegion></affiliation></author><author><name sortKey="De Giorgi, Ugo" sort="De Giorgi, Ugo" uniqKey="De Giorgi U" first="Ugo" last="De Giorgi">Ugo De Giorgi</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola</wicri:regionArea><wicri:noRegion>Meldola</wicri:noRegion></affiliation></author><author><name sortKey="Grunwald, Viktor" sort="Grunwald, Viktor" uniqKey="Grunwald V" first="Viktor" last="Grünwald">Viktor Grünwald</name><affiliation wicri:level="1"><nlm:affiliation>Hanover Medical School, Hanover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hanover Medical School, Hanover</wicri:regionArea><wicri:noRegion>Hanover</wicri:noRegion><wicri:noRegion>Hanover</wicri:noRegion><wicri:noRegion>Hanover</wicri:noRegion></affiliation></author><author><name sortKey="Davis, Ian D" sort="Davis, Ian D" uniqKey="Davis I" first="Ian D" last="Davis">Ian D. Davis</name><affiliation wicri:level="1"><nlm:affiliation>Monash University Eastern Health Clinical School, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University Eastern Health Clinical School, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae-Lyun" last="Lee">Jae-Lyun Lee</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Central de Asturias, Oviedo, Asturias</wicri:regionArea><wicri:noRegion>Asturias</wicri:noRegion></affiliation></author><author><name sortKey="Urbanowitz, Gladys" sort="Urbanowitz, Gladys" uniqKey="Urbanowitz G" first="Gladys" last="Urbanowitz">Gladys Urbanowitz</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cai, Can" sort="Cai, Can" uniqKey="Cai C" first="Can" last="Cai">Can Cai</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Squires, Matthew" sort="Squires, Matthew" uniqKey="Squires M" first="Matthew" last="Squires">Matthew Squires</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Marker, Mahtab" sort="Marker, Mahtab" uniqKey="Marker M" first="Mahtab" last="Marker">Mahtab Marker</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shi, Michael M" sort="Shi, Michael M" uniqKey="Shi M" first="Michael M" last="Shi">Michael M. Shi</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24556040</idno><idno type="pmid">24556040</idno><idno type="doi">10.1016/S1470-2045(14)70030-0</idno><idno type="wicri:Area/PubMed/Corpus">003913</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003913</idno><idno type="wicri:Area/PubMed/Curation">003798</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003798</idno><idno type="wicri:Area/PubMed/Checkpoint">003798</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003798</idno><idno type="wicri:Area/Ncbi/Merge">001801</idno><idno type="wicri:Area/Ncbi/Curation">001801</idno><idno type="wicri:Area/Ncbi/Checkpoint">001801</idno><idno type="wicri:Area/Main/Merge">003A56</idno><idno type="wicri:Area/Main/Curation">003A13</idno><idno type="wicri:Area/Main/Exploration">003A13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.</title><author><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name><affiliation wicri:level="2"><nlm:affiliation>Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Sloan-Kettering Cancer Center, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Porta, Camillo" sort="Porta, Camillo" uniqKey="Porta C" first="Camillo" last="Porta">Camillo Porta</name><affiliation wicri:level="1"><nlm:affiliation>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Matteo University Hospital Foundation, Pavia</wicri:regionArea><wicri:noRegion>Pavia</wicri:noRegion></affiliation></author><author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name><affiliation wicri:level="2"><nlm:affiliation>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Comprehensive Cancer Centers of Nevada, Las Vegas, NV</wicri:regionArea><placeName><region type="state">Nevada</region></placeName></affiliation></author><author><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name><affiliation wicri:level="3"><nlm:affiliation>San Camillo and Forlanini Hospitals, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>San Camillo and Forlanini Hospitals, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Szczylik, Cezary" sort="Szczylik, Cezary" uniqKey="Szczylik C" first="Cezary" last="Szczylik">Cezary Szczylik</name><affiliation wicri:level="1"><nlm:affiliation>Military Institute of Health Services in Warsaw, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Military Institute of Health Services in Warsaw, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Zolnierek, Jakub" sort="Zolnierek, Jakub" uniqKey="Zolnierek J" first="Jakub" last="Zolnierek">Jakub Zolnierek</name><affiliation wicri:level="1"><nlm:affiliation>Maria Sklodowska-Curie Institute, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Maria Sklodowska-Curie Institute, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Kollmannsberger, Christian" sort="Kollmannsberger, Christian" uniqKey="Kollmannsberger C" first="Christian" last="Kollmannsberger">Christian Kollmannsberger</name><affiliation wicri:level="1"><nlm:affiliation>BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>BC Cancer Agency Vancouver Cancer Centre, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name><affiliation wicri:level="3"><nlm:affiliation>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name><affiliation wicri:level="1"><nlm:affiliation>Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Sunnybrook Odette Cancer Centre, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Melichar, Bohuslav" sort="Melichar, Bohuslav" uniqKey="Melichar B" first="Bohuslav" last="Melichar">Bohuslav Melichar</name><affiliation wicri:level="1"><nlm:affiliation>Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Palacký University Medical School and Teaching Hospital, Olomouc</wicri:regionArea><wicri:noRegion>Olomouc</wicri:noRegion></affiliation></author><author><name sortKey="De Giorgi, Ugo" sort="De Giorgi, Ugo" uniqKey="De Giorgi U" first="Ugo" last="De Giorgi">Ugo De Giorgi</name><affiliation wicri:level="1"><nlm:affiliation>IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola</wicri:regionArea><wicri:noRegion>Meldola</wicri:noRegion></affiliation></author><author><name sortKey="Grunwald, Viktor" sort="Grunwald, Viktor" uniqKey="Grunwald V" first="Viktor" last="Grünwald">Viktor Grünwald</name><affiliation wicri:level="1"><nlm:affiliation>Hanover Medical School, Hanover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Hanover Medical School, Hanover</wicri:regionArea><wicri:noRegion>Hanover</wicri:noRegion><wicri:noRegion>Hanover</wicri:noRegion><wicri:noRegion>Hanover</wicri:noRegion></affiliation></author><author><name sortKey="Davis, Ian D" sort="Davis, Ian D" uniqKey="Davis I" first="Ian D" last="Davis">Ian D. Davis</name><affiliation wicri:level="1"><nlm:affiliation>Monash University Eastern Health Clinical School, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Monash University Eastern Health Clinical School, Melbourne, VIC</wicri:regionArea><wicri:noRegion>VIC</wicri:noRegion></affiliation></author><author><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae-Lyun" last="Lee">Jae-Lyun Lee</name><affiliation wicri:level="3"><nlm:affiliation>Asan Medical Center, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Asan Medical Center, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Central de Asturias, Oviedo, Asturias</wicri:regionArea><wicri:noRegion>Asturias</wicri:noRegion></affiliation></author><author><name sortKey="Urbanowitz, Gladys" sort="Urbanowitz, Gladys" uniqKey="Urbanowitz G" first="Gladys" last="Urbanowitz">Gladys Urbanowitz</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Cai, Can" sort="Cai, Can" uniqKey="Cai C" first="Can" last="Cai">Can Cai</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Squires, Matthew" sort="Squires, Matthew" uniqKey="Squires M" first="Matthew" last="Squires">Matthew Squires</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Marker, Mahtab" sort="Marker, Mahtab" uniqKey="Marker M" first="Mahtab" last="Marker">Mahtab Marker</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Shi, Michael M" sort="Shi, Michael M" uniqKey="Shi M" first="Michael M" last="Shi">Michael M. Shi</name><affiliation wicri:level="2"><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Novartis Pharmaceuticals Corporation, East Hanover, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name><affiliation wicri:level="1"><nlm:affiliation>Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents (therapeutic use)</term><term>Benzimidazoles (adverse effects)</term><term>Benzimidazoles (therapeutic use)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (mortality)</term><term>Carcinoma, Renal Cell (secondary)</term><term>Female</term><term>Humans</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (mortality)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Niacinamide (adverse effects)</term><term>Niacinamide (analogs & derivatives)</term><term>Niacinamide (therapeutic use)</term><term>Phenylurea Compounds (adverse effects)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Quinolones (adverse effects)</term><term>Quinolones (therapeutic use)</term><term>Vascular Endothelial Growth Factor A (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Benzimidazoles (effets indésirables)</term><term>Benzimidazoles (usage thérapeutique)</term><term>Facteur de croissance endothéliale vasculaire de type A (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Mâle</term><term>Métastase tumorale</term><term>Nicotinamide (analogues et dérivés)</term><term>Nicotinamide (effets indésirables)</term><term>Nicotinamide (usage thérapeutique)</term><term>Néphrocarcinome (mortalité)</term><term>Néphrocarcinome (secondaire)</term><term>Néphrocarcinome (traitement médicamenteux)</term><term>Phénylurées (effets indésirables)</term><term>Phénylurées (usage thérapeutique)</term><term>Quinolinone (effets indésirables)</term><term>Quinolinone (usage thérapeutique)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du rein (mortalité)</term><term>Tumeurs du rein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Benzimidazoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Quinolones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Niacinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Vascular Endothelial Growth Factor A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Benzimidazoles</term><term>Niacinamide</term><term>Phenylurea Compounds</term><term>Protein Kinase Inhibitors</term><term>Quinolones</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Nicotinamide</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type A</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Benzimidazoles</term><term>Nicotinamide</term><term>Phénylurées</term><term>Quinolinone</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Néphrocarcinome</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Renal Cell</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Néphrocarcinome</term><term>Tumeurs du rein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Benzimidazoles</term><term>Inhibiteurs de protéines kinases</term><term>Nicotinamide</term><term>Phénylurées</term><term>Quinolinone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Métastase tumorale</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Corée du Sud</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pologne</li><li>République tchèque</li><li>Suisse</li><li>États-Unis</li></country><region><li>Latium</li><li>Nevada</li><li>New Jersey</li><li>Région capitale de Séoul</li><li>État de New York</li></region><settlement><li>Rome</li><li>Séoul</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Motzer, Robert J" sort="Motzer, Robert J" uniqKey="Motzer R" first="Robert J" last="Motzer">Robert J. Motzer</name></region><name sortKey="Cai, Can" sort="Cai, Can" uniqKey="Cai C" first="Can" last="Cai">Can Cai</name><name sortKey="Marker, Mahtab" sort="Marker, Mahtab" uniqKey="Marker M" first="Mahtab" last="Marker">Mahtab Marker</name><name sortKey="Shi, Michael M" sort="Shi, Michael M" uniqKey="Shi M" first="Michael M" last="Shi">Michael M. Shi</name><name sortKey="Urbanowitz, Gladys" sort="Urbanowitz, Gladys" uniqKey="Urbanowitz G" first="Gladys" last="Urbanowitz">Gladys Urbanowitz</name><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name></country><country name="Italie"><noRegion><name sortKey="Porta, Camillo" sort="Porta, Camillo" uniqKey="Porta C" first="Camillo" last="Porta">Camillo Porta</name></noRegion><name sortKey="De Giorgi, Ugo" sort="De Giorgi, Ugo" uniqKey="De Giorgi U" first="Ugo" last="De Giorgi">Ugo De Giorgi</name><name sortKey="Sternberg, Cora N" sort="Sternberg, Cora N" uniqKey="Sternberg C" first="Cora N" last="Sternberg">Cora N. Sternberg</name></country><country name="Pologne"><noRegion><name sortKey="Szczylik, Cezary" sort="Szczylik, Cezary" uniqKey="Szczylik C" first="Cezary" last="Szczylik">Cezary Szczylik</name></noRegion><name sortKey="Zolnierek, Jakub" sort="Zolnierek, Jakub" uniqKey="Zolnierek J" first="Jakub" last="Zolnierek">Jakub Zolnierek</name></country><country name="Canada"><noRegion><name sortKey="Kollmannsberger, Christian" sort="Kollmannsberger, Christian" uniqKey="Kollmannsberger C" first="Christian" last="Kollmannsberger">Christian Kollmannsberger</name></noRegion><name sortKey="Bjarnason, Georg A" sort="Bjarnason, Georg A" uniqKey="Bjarnason G" first="Georg A" last="Bjarnason">Georg A. Bjarnason</name></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Rha, Sun Young" sort="Rha, Sun Young" uniqKey="Rha S" first="Sun Young" last="Rha">Sun Young Rha</name></region><name sortKey="Lee, Jae Lyun" sort="Lee, Jae Lyun" uniqKey="Lee J" first="Jae-Lyun" last="Lee">Jae-Lyun Lee</name></country><country name="République tchèque"><noRegion><name sortKey="Melichar, Bohuslav" sort="Melichar, Bohuslav" uniqKey="Melichar B" first="Bohuslav" last="Melichar">Bohuslav Melichar</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Grunwald, Viktor" sort="Grunwald, Viktor" uniqKey="Grunwald V" first="Viktor" last="Grünwald">Viktor Grünwald</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Davis, Ian D" sort="Davis, Ian D" uniqKey="Davis I" first="Ian D" last="Davis">Ian D. Davis</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Esteban, Emilio" sort="Esteban, Emilio" uniqKey="Esteban E" first="Emilio" last="Esteban">Emilio Esteban</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Squires, Matthew" sort="Squires, Matthew" uniqKey="Squires M" first="Matthew" last="Squires">Matthew Squires</name></noRegion></country><country name="France"><noRegion><name sortKey="Escudier, Bernard" sort="Escudier, Bernard" uniqKey="Escudier B" first="Bernard" last="Escudier">Bernard Escudier</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24556040
|texte= Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24556040" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |